Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer
Paul J FitzgeraldThe Zanvyl Krieger Mind/Brain Institute, Solomon H. Snyder, Department of Neuroscience, Johns Hopkins University, Baltimore, MD, USAAbstract: Recently, I put forth the hypothesis that the signaling molecule, norepinephrine (NE), is an etiological factor in a number of types of cance...
Main Author: | Paul J Fitzgerald |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-12-01
|
Series: | Clinical Epidemiology |
Online Access: | http://www.dovepress.com/testing-whether-drugs-that-weaken-norepinephrine-signaling-prevent-or--a3879 |
Similar Items
-
Many Drugs of Abuse May Be Acutely Transformed to Dopamine, Norepinephrine and Epinephrine In Vivo
by: Paul J. Fitzgerald
Published: (2021-10-01) -
Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint
by: Fitzgerald PJ
Published: (2012-06-01) -
Norepinephrine May Oppose Other Neuromodulators to Impact Alzheimer’s Disease
by: Paul J. Fitzgerald
Published: (2021-07-01) -
Is There a Novel Biosynthetic Pathway in Mice That Converts Alcohol to Dopamine, Norepinephrine and Epinephrine?
by: Paul J. Fitzgerald
Published: (2022-04-01) -
Point-of-Care Testing – Biosensor for Norepinephrine Determination
by: Sylwia Baluta, et al.
Published: (2020-06-01)